Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION: Single-agent IO has demonstrated activity in patients with relapsed B-cell ALL and non-Hodgkin lymphoma (NHL). It has also demonstrated favorable early results when combined with chemotherapy in older patients with ALL. There is potential for IO to be combined with other targeted therapies under development for these diseases; data are still early and further studies of IO are warranted. While the pivotal randomized study of IO for relapsed NHL versus physician's choice did not show a statistically significant advantage in response rate, the results of the pivotal study in ALL are not yet available.
|
Authors | Maro Ohanian, Hagop Kantarjian, Daniel Guy, Deborah Thomas, Elias Jabbour, Susan O'Brien |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 15
Issue 4
Pg. 601-11
(Apr 2015)
ISSN: 1744-7682 [Electronic] England |
PMID | 25775418
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Sialic Acid Binding Ig-like Lectin 2
- Inotuzumab Ozogamicin
|
Topics |
- Acute Disease
- Animals
- Antibodies, Monoclonal
(pharmacology, therapeutic use)
- Antibodies, Monoclonal, Humanized
(pharmacology, therapeutic use)
- B-Lymphocytes
(drug effects, immunology, metabolism)
- Humans
- Inotuzumab Ozogamicin
- Leukemia, B-Cell
(drug therapy, immunology, metabolism)
- Lymphoma, Non-Hodgkin
(drug therapy, immunology, metabolism)
- Sialic Acid Binding Ig-like Lectin 2
(antagonists & inhibitors, biosynthesis)
|